The aim of this study is to analyze the impact of the Hsp90 inhibitor, 17-AAG, on cellular signaling in the context of atopic dermatitis therapy. The research focuses on understanding how 17-AAG influences key signaling proteins involved in the pathogenesis of atopic dermatitis.
- Immortalized Keratinocyte Cell Line (HaCaT): The HaCaT cell line was used as a model for keratinocytes.
- Stimuli: HaCaT cells were stimulated with IFN-γ/TNF-α to simulate inflammatory conditions relevant to atopic dermatitis.
- Cells were cultured in the presence or absence of 17-AAG, an Hsp90 inhibitor.
The phosphorylation status of the following signaling proteins was analyzed:
- STAT-1
- STAT-3
- STAT-6
- ERK
- MAPK
The activation of these proteins, as well as the role of Hsp90 acetylation (acLys284/292), was assessed in activated HaCaT cells using immunoblotting.
Densynometry was conducted using ImageJ. The results were then imported into Excel, where they were normalized against β-actin. Subsequently, the data was transferred into Visual Studio Code for further analysis using Python.
Our data suggest that Hsp90 inhibition via 17-AAG has differential effects across signaling pathways:
- STAT3 and MAPK/ERK are suppressed by both 0.1 µM and 1 µM, consistent with reduced pro-inflammatory signaling and cell growth.
- STAT6, in contrast, is only upregulated at higher concentrations, possibly indicating a compensatory pathway activation or cell-specific signaling rewiring.
- These effects align with the role of Hsp90 in stabilizing a broad range of signaling proteins, including kinases and transcription factors. Its inhibition thus causes a domino-like collapse of multiple intracellular signaling cascades.
- Such dose-dependent and pathway-specific modulation makes 17-AAG a promising molecule in the context of targeted therapeutic strategies for neurodegenerative conditions, where selective suppression of inflammatory or proliferative pathways is desirable.